Novo Nordisk enrolls Innovex for menopause drugs sales
Novo Nordisk Pharmaceuticals in the USA and Innovex, the commercialization unit of Quintiles Transnational, have announced an agreement to deploy a force of specialty sales representatives to provide support for hormone therapy Activella (estradiol/norethindrone acetate tablets) and Vagifem (estradiol vaginal tablets).
Under the terms of the deal, Innovex will provide a dedicated team of 100 sales representatives in the USA for a two-year term. Innovex provides pharmaceutical companies with experienced representatives who have expertise in specific therapeutic areas to maximize opportunities for interaction with physicians.
Approved in the USA in November 1998, Activella is a continuous, combined once-daily tablet for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with an intact uterus. The product is marketed in countries outside the USA by parent company Denmark's Novo Nordisk under the brand Activelle.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze